Xenetic Biosciences (NASDAQ:XBIO) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Xenetic Biosciences (NASDAQ:XBIO) posted its quarterly earnings results on Tuesday. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14), Zacks reports. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 47.21%. The business had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.75 million.

Xenetic Biosciences Stock Up 0.3 %

NASDAQ:XBIO traded up $0.01 on Thursday, reaching $3.66. 11,320 shares of the company’s stock were exchanged, compared to its average volume of 11,227. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.20. The firm has a market capitalization of $5.64 million, a price-to-earnings ratio of -1.47 and a beta of 2.25. The business has a fifty day moving average of $3.89 and a 200-day moving average of $3.93.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a report on Tuesday, August 20th.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.